



PRESS RELEASE

## Collectis Announces Presentations at Upcoming Conferences

**New York, November 30, 2015** – Collectis (Alternext: ALCLS – Nasdaq: CLLS), on developing immunotherapies based on gene edited CAR-T cells (UCART), today announced **presentations at the Piper Jaffray 27th Annual Healthcare Conference and the Oppenheimer 26th Annual Healthcare Conference.**

- December 2, 2015 - Piper Jaffray 27th Annual Healthcare Conference - NYC Fireside chat presentation from 1:00pm to 1:25pm ET at the New York Palace Hotel
- December 9, 2015 - Oppenheimer 26th Annual Healthcare Conference - NYC Company presentation from 9:10am to 9:40am ET at the Westin New York Grand Central

### About Collectis

Collectis is a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART). The company's mission is to develop a new generation of cancer therapies based on engineered T-cells. Collectis capitalizes on its 15 years of expertise in genome engineering - based on its flagship TALEN<sup>®</sup> products and meganucleases and pioneering electroporation PulseAgile technology - to create a new generation of immunotherapies. CAR technologies are designed to target surface antigens expressed on cells. Using its life-science-focused, pioneering genome-engineering technologies, Collectis' goal is to create innovative products in multiple fields and with various target markets. Collectis is listed on the Nasdaq market (ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS). To find out more about us, visit our website: [www.collectis.com](http://www.collectis.com)

Talking about gene editing? We do it.  
TALEN<sup>®</sup> is a registered trademark owned by the Collectis Group.

**For further information, please contact:**

### Media contacts

Jennifer Moore, VP Communications  
Phone: +1 917-580-1088  
email: [media@collectis.com](mailto:media@collectis.com)

Caitlin Kasunich / Dixon Moretz  
KCSA Strategic Communications  
Phone: +1 212.896.1241 / +1 212.896.1251  
email: [ckasunich@kcsa.com](mailto:ckasunich@kcsa.com) / [dmoretz@kcsa.com](mailto:dmoretz@kcsa.com)

**Investor relations contact**

Simon Harnest, VP Finance and Investor Relations

Phone: +1 646-385-9008

email: [simon.harnest@collectis.com](mailto:simon.harnest@collectis.com)